Lipids
Network M-A | Comparative efficacy of lipid‐lowering therapies added to maximally tolerated statins for the reduction of LDL cholesterol.
11 Sep, 2022 | 22:38h | UTC
2022 ACC Expert Consensus | Role of nonstatin therapies for LDL-cholesterol lowering and managing cardiovascular disease risk.
2 Sep, 2022 | 13:17h | UTCNews Release: ACC Issues Guidance to Address New Nonstatin Therapies – American College of Cardiology
Commentary: New on the Scene Nonstatin Drugs: Experts Provide Guidance – TCTMD
Commentary on Twitter
? ACC releases Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
Read more: https://t.co/WDOSPgQ1bx #ACCClinicalDoc pic.twitter.com/nt8S2pdBgD
— American College of Cardiology (@ACCinTouch) August 25, 2022
#ESCCongress | Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials.
30 Aug, 2022 | 12:16h | UTCNews Release: Cardiovascular protection from statins greatly outweighs the risk of muscle symptoms – European Society of Cardiology
Commentary: Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration – TCTMD
Consensus Statement | Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis.
30 Aug, 2022 | 12:10h | UTC
Commentary on Twitter
Lipoprotein(a) in atherosclerotic CV and aortic stenosis – a European Atherosclerosis Society consensus statement https://t.co/Bzzpd3Bx8M
#EHJ #ESCCongress #ESCYoung @escardio @ehj_ed @rladeiraslopes pic.twitter.com/ZcqaPe581K
— European Society of Cardiology Journals (@ESC_Journals) August 29, 2022
#ESCCongress | Study shows long-term Evolocumab appears to be safe in patients with established atherosclerotic cardiovascular disease.
30 Aug, 2022 | 12:12h | UTCNews Release: Long-term evolocumab therapy leads to further reductions in cardiovascular events – European Society of Cardiology
Original Article: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease – New England Journal of Medicine
Commentary on Twitter
#OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs was associated w/ persistently low rates and greater reduction in MACE compared w/ delayed treatment initiation among patients w… https://t.co/9g97s4MZSt pic.twitter.com/y5uN53gdKo
— Circulation (@CircAHA) August 29, 2022
USPSTF Recommendation Statement | Statin use for the primary prevention of cardiovascular disease in adults.
24 Aug, 2022 | 14:21h | UTCEditorials:
Author Interview: USPSTF Recommendation: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults – JAMA
Patient Page: Statins for the Prevention of Cardiovascular Disease – JAMA
Commentary: Latest statins guidance keeps more conservative approach to preventing first stroke or heart attack – CNN
Position Paper | Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients.
16 Aug, 2022 | 13:42h | UTC
Clinical Practice Update | The detection, evaluation, and management of dyslipidemia in children and adolescents.
15 Aug, 2022 | 12:12h | UTC
Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function.
12 Aug, 2022 | 15:11h | UTCCommentaries:
Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution – TCTMD
In a cohort study with a median follow‐up of 23.2 years, both very low and very high LDL‐C levels are associated with increased risk of cardiovascular mortality in the general population.
4 Aug, 2022 | 14:25h | UTC
Position Paper | Red yeast rice for dyslipidemias and cardiovascular risk reduction.
29 Jul, 2022 | 12:35h | UTC
Consensus statement on the management of familial hypercholesterolemia.
28 Jul, 2022 | 13:16h | UTC
Chasing LDL cholesterol to the bottom — PCSK9 in perspective.
22 Jul, 2022 | 11:36h | UTCChasing LDL cholesterol to the bottom — PCSK9 in perspective – Nature Cardiovascular Research (if the link is paywalled, try this one)
Commentary on Twitter
Review| @LaleTokgozoglu and Peter Libby discuss the management of #atherogenic #LDL cholesterol with an emphasis on the role #PCSK9 inhibition strategies https://t.co/k1wPKAdotU
— Nature Cardiovascular Research (@NatureCVR) June 17, 2022
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
21 Jul, 2022 | 13:11h | UTC
Open-label RCT | Moderate-intensity statin plus ezetimibe is noninferior to high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease.
20 Jul, 2022 | 12:32h | UTCLong-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolemia.
18 Jul, 2022 | 11:18h | UTC
Relationship between low-density lipoprotein cholesterol, lipid-lowering agents and risk of stroke: a meta-analysis of observational studies (n = 355,591) and randomized controlled trials (n = 165,988).
18 Jul, 2022 | 11:09h | UTC
NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient.
12 Jul, 2022 | 12:48h | UTCCommentary: National Lipid Association Scientific Statement on Statin Intolerance – American College of Cardiology
Key studies published in 2021 related to primary prevention of atherosclerotic cardiovascular disease.
5 Jul, 2022 | 12:12h | UTCHighlights in ASCVD Primary Prevention for 2021 – Journal of the American Heart Association